Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials

References

• Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–1261. doi: 10.1053/J.GASTRO.2013.01.068
   PubMed Web of Science ®Google Scholar
• Xiao AY, Tan MLY, Wu LM, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol. 2016;1(1):45–55. doi: 10.1016/S2468-1253(16)30004-8
   PubMed Web of Science ®Google Scholar
• Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132(5):2022–2044. doi: 10.1053/J.GASTRO.2007.03.065
   PubMed Web of Science ®Google Scholar
• Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet. 2008;371(9607):143–152. doi: 10.1016/S0140-6736(08)60107-5
   PubMed Web of Science ®Google Scholar
• Alhaddad O, Elsabaawy M, Elfauomy M, et al. Updates in drug-induced acute pancreatitis. doi: 10.1186/s43066-020-00059-3
   Google Scholar
• Gonzalez-Perez A, Schlienger RG, García Rodríguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care. 2010;33(12):2580–2585. doi: 10.2337/dc10-0842
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Li D, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control Consortium. Ann Oncol. 2014;25(10):2065–2072. doi: 10.1093/ANNONC/MDU276
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–156. doi: 10.1053/J.GASTRO.2011.02.018
   PubMed Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–539. doi: 10.1001/JAMAINTERNMED.2013.2720
   PubMed Web of Science ®Google Scholar
• Giorda CB, Nada E, Tartaglino B, et al. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diab Obes Metab. 2014;16(11):1041–1047. doi: 10.1111/dom.12297
   PubMed Web of Science ®Google Scholar
• Tang H, Yang K, Li X, et al. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2020;29(2):161–172. doi: 10.1002/PDS.4943
   PubMed Web of Science ®Google Scholar
• Dicembrini I, Montereggi C, Nreu B, et al. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabet Res Clin Pract. 2020;159:107981. doi: 10.1016/j.diabres.2019.107981
   PubMed Web of Science ®Google Scholar
• Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diab Obes Metab. 2017;19(9):1233–1241. doi: 10.1111/dom.12926
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Marchionni N, et al. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care. 2008;31(7):1455–1460. doi: 10.2337/DC07-2308
   PubMed Web of Science ®Google Scholar
• Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009;58(7):1604–1615. doi: 10.2337/DB09-0058
   PubMed Web of Science ®Google Scholar
• Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53(1):153–159. doi: 10.1007/S00125-009-1515-4
   PubMed Web of Science ®Google Scholar
• Palapra H, Viswam SK, Kalaiselvan V, et al. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. Int J Clin Pharm. 2022;44(6):1425–1433. doi: 10.1007/s11096-022-01476-7
   PubMed Web of Science ®Google Scholar
• Böhm R. Primer on disproportionality analysis.
   Google Scholar
• Böhm R, von Hehn L, Herdegen T, et al. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753. doi: 10.1371/journal.pone.0157753
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4
   PubMedGoogle Scholar
• Dholakia K, Pitchumoni CS, Agarwal N. How often are liver function tests normal in acute biliary pancreatitis? J Clin Gastroenterol. 2004;38(1):81–83. doi: 10.1097/00004836-200401000-00017
   PubMed Web of Science ®Google Scholar
• DM K, CJ R, M P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a. Diabetes Care. 2006;29(5):1016–1023. doi: 10.2337/dc05-1146
   PubMed Web of Science ®Google Scholar
• Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diab Obes Metab. 2015;17(2):179–187. doi: 10.1111/dom.12414
   PubMed Web of Science ®Google Scholar
• Hidayat K, Zhou YY, Du HZ, et al. A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer. Pharmacoepidemiol Drug Saf. 2023;32(2):107–125. doi: 10.1002/pds.5550
   PubMed Web of Science ®Google Scholar
• Kanasaki K, Qu S, Yamamoto F, et al. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. Expert Opin Drug Saf. 2022;21(3):425–434. doi: 10.1080/14740338.2022.1999409
   PubMed Web of Science ®Google Scholar
• Caparrotta TM, Templeton JB, Clay TA, et al. Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. Diabetes Ther. 2021;12(4):969–989. doi: 10.1007/S13300-021-01021-1
   PubMed Web of Science ®Google Scholar
• Abd El Aziz M, Cahyadi O, Meier JJ, et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diab Obes Metab. 2020;22(4):699–704. doi: 10.1111/dom.13924
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen X, Lu P, et al. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017;16(1):31. doi: 10.1186/s12933-017-0512-z
   PubMed Web of Science ®Google Scholar
• Dicembrini I, Montereggi C, Nreu B, et al. Pancreatitis and pancreatic cancer in patients treated with Dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabet Res Clin Pract. 2020;159:107981. doi: 10.1016/j.diabres.2019.107981
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang M, Wang X, et al. Comparison of New glucose-lowering drugs on the risk of pancreatitis in type 2 diabetes: a network meta-analysis. Endocr Pract. 2022;28(3):333–341. doi: 10.1016/j.eprac.2021.12.007
   PubMed Web of Science ®Google Scholar
• Knapen LM, de Jong RGPJ, Driessen JHM, et al. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. Diab Obes Metab. 2017;19(3):401–411. doi: 10.1111/DOM.12833
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Pedersen L, Møller N, et al. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care. 2015;38(6):1089–1098. doi: 10.2337/DC13-2983
   PubMed Web of Science ®Google Scholar
• FDA drug safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes FDA.
   Google Scholar
• Ryder REJ. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabet Med. 2013;30(10):1148–1155. doi: 10.1111/dme.12301
   PubMed Web of Science ®Google Scholar
• Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–2604. doi: 10.2337/db12-1686
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Keller E, et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol. 2007;292(3). doi: 10.1152/AJPCELL.00406.2006
   PubMed Web of Science ®Google Scholar
• Ouyang G, Pan G, Liu Q, et al. The global, regional, and national burden of pancreatitis in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. BMC Med. 2017;2020:1–13. doi: 10.1186/s12916-020-01859-5
   Google Scholar
• Caparrotta TM, Greenhalgh AM, Osinski K, et al. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. Diabetes Ther. 2021;12(4):991–1028. doi: 10.1007/S13300-021-01004-2
   PubMed Web of Science ®Google Scholar
• Frent I, Bucsa C, Leucuta D, et al. An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: a VigiBase study. Pharmacoepidemiol Drug Saf. 2021;30(10):1428–1440. doi: 10.1002/pds.5313
   PubMed Web of Science ®Google Scholar
• Zhou PT, Li B, Liu FR, et al. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget. 2017;8(15):25242–25250. doi: 10.18632/oncotarget.15692
   PubMedGoogle Scholar
• Colmers IN, Bowker SL, Tjosvold LA, et al. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes metab. 2012;38(6):485–506. doi: 10.1016/j.diabet.2012.08.011
   PubMed Web of Science ®Google Scholar